Abstract 2118: ABN501: A CLDN3-targeted monoclonal antibody with proven safety, pharmacokinetics, and synergistic anti-tumor efficacy

Authors: Saehyung Lee, Jae Choi, Sunghyun Hong, Ha Yeon Park, Ho Jin Lee, Jaemun Kim, Sangin Lee, Seung Hwa Jung, Myeung Ryun Seo, Hobin Yang, Sungyoul Hong, Jun Young Choi, Na Young Kim, Young Kee Shin

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-2118

Source: Full article


Abstract

Abstract